悪液質合併胃がんにおける早期のアナモレリン投与の有用性の検討
松本俊彦、佐竹悠良、安井久晃
2024.2.28 - 2024.3.1
|
Establishing a patient-derived tumour spheroid model using endoscopic biopsy specimens of gastrointestinal cancers
H. Satake, Y. Ykurioka, T. Sato, S. Ojima, S. Boku, Y. Takemura
2024.2.26 - 2024.2.28
|
Anti-EGFR therapy for RAS mutant mCRC without RAS mutations in ctDNA after 1st or 2nd-line chemotherapy: JACCRO CC-17
Yukari Ono, Naoki Izawa, Yuki Matsubara, Shinichi Nishina, Tadamichi Denda, Hirofumi Ota, Takuya Tokunaga, Lin Fung Chan, Yoshiaki Shindo, Hozumi Shimokawa, Hideto Fujita, Ken Okamoto, Tomoyuki Ishiguro, Yasuhiro Sakamoto, Yoshinori Kagawa, Hironaga Satake, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii, Yu Sunakawa
2024.2.22 - 2024.2.24
|
Randomized phase III study of bi-weekly FTD/TPI plus BEV vs. FTD/TPI monotherapy for chemorefractory mCRC:
Yasunobu Ishizuka, Hironaga Satake, Kentaro Yamazaki, Yusuke Suwa, Takahiro Tsushima,Shogen Boku, Atsuo Takashima, Toshifumi Yamaguchi, Masako Asayama, Mitsuru Yokota
2024.2.22 - 2024.2.24
|
The scoring system for selecting Nivolumab or Irinotecan in the later-line chemotherapy for advanced gastric cancer: A Japanese multicenter retrospective study
Takeshi Kawakami, Takeshi Suzuki, Yusuke Amanuma, Masahiko Aoki, Yoshiyuki Yamamoto, Keitaro Shimozaki, Hironaga Satake, Masanori Nojima, Narikazu Boku, Daisuke Takahari,Ryo Kitabayashi, Yusuke Sano, Haruhiko Fukuda, Tetsuya Hamaguchi, Yukihide Kanemitsu
2024.2.22 - 2024.2.24
|
周術期治療が奏効した副鼻腔Ewing肉腫の一例
Yusuke Kurioka, Sakie Ojima, Takuya Sato, Hajime Kosai, Masahiro Komori, Hironaga Satake
2024.2.22 - 2024.2.24
|
A Case Report: Immune-Related Polymyalgia Rheumatica-Like Syndrome After Nivolumab Monotherapy For Tongue Cancer
Takuya Sato, Hironaga Satake
2024.2.22 - 2024.2.24
|
Efficacy and safety of chemotherapy plus nivolumab for advanced gastric cancer with ascites.
Toshihiko Matsumoto, Chinatsu Makiyama, Akio Nakasya, Hiroki Nagai, Tatsuki Ikoma, Tomoyo Yasuda,Shogen Boku, Nobuhiro Shibata, Takao Tsuduki, Hisateru Yasui, Hironaga Satake
2024.2.22 - 2024.2.24
|
Oral Session 3 消化器 1（胃がん）
佐竹悠良
2024.2.21 - 2024.2.24
|
An observational study on treatment patterns and outcomes among patients with metastatic or recurrent esophageal cancer: Real world data and empirical analyses in Japan (POME)
Shun Yamamoto, Ken Kato, Hiroshi Saek, Shigenori Kadowaki, Keiko Minashi, Yuki Kasahara, Motoo Nomura, Tomoyo Yasuda, Yusuke Sato, Kazuo Koyanagi, Naoki Izawa, Morihito Okada, Hironaga Satake, Shuko Morita, Masahiro Goto, Takako Yoshii, Sachiko Yamamoto, Makiko Izawa, Kohei Uemura, Kei Muro
2024.1.18 - 2024.2.20
|
First report of the randomized phase III study of bi-weekly trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) vs.
FTD/TPI monotherapy for chemorefractory metastatic colorectal cancer (mCRC): JCOG2014(ROBiTS）
Hironaga Satake, Kentaro Yamazaki, Yusuke Suwa, Takahiro Tsushima, Yasunobu Ishizuka, Shogen Boku, Atsuo Takashima, Toshifumi Yamaguchi, Masako Asayama, Mitsuru Yokota, Koji Numata10, Takashi Ohta11
, Hisateru Yasui12, Yosuke Kito13, Yasumasa Takii14, Ryo Kitabayashi15, Yusuke Sano15, Haruhiko Fukuda15, Tetsuya Hamaguchi16
, Yukihide Kanemitsu
2024.1.18 - 2024.1.20
|
胃癌治療UPDATE
佐竹悠良
2023.11.2 - 2023.11.5
|
The efficacy of anti-EGFR therapy for RAS mutant metastatic colorectal cancer (mCRC) patients with RAS mutation negative in circulating-tumor DNA (ctDNA) after 1st or 2nd-line chemotherapy
Naoki Izawa, Toshihiro Kudo, Satoshi Yuki, Michio Nakamura, Dai Manaka, Yosuke Kumekawa, Takashi Mine, Tatsuya Okuno, Hisanobu Oda, Tamotsu Sagawa, Takashi Kawai, Tatsushi Shingai, Masahito Kotaka, Kenji Kobayashi, Yoshinori Kagawa, Hironaga Satake, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii, Yu Sunakawa
2023.10.22 - 2023.10.24
|
The primary results of an intergroup phase III randomized controlled trial comparing ramucirumab plus irinotecan with irinotecan in the third or later line treatment beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG Trial).
S. Kadowaki, D. Sakai, R. Kawabata, H. Hara, H. Yasui, M. Takahashi, M. Hirao, H. Imai, K. Minashi, T. Kawakami, H. Satake, J. Matsuyama, Y. Sakamoto, K. Sawada, M. Kataoka, H. Kawakami, T. Shimokawa, N. Boku, T. Satoh
2023.10.22 - 2023.10.24
|
A biomarker analysis from EFFORT study; a prospective study of FOLFIRI plus aflibercept as second-line treatment after failure of FOLFOXIRI plus BEV in patients with unresectable colorectal cancer
松本俊彦， 安藤幸滋， 佐竹悠良， 根来裕二， 金城達也， 弓削浩太郎， 馬場研二， 折田博之， 平田敬治， 下川元継， 牧山明資， 佐伯浩司， 沖英次， 馬場秀夫
2023.10.19 - 2023.10.21
|
A Multicenter Randomized Phase II Trial Comparing CAPOXIRI+Bevacizumab? with FOLFOXIRI+Bevacizumab as First-line Treatment in Patients with Metastatic Colorectal Cancer: QUATTRO-II Study
H. Yasui, H. Bando, H. Satake, D. Kotani, T. Hamaguchi, M. Kotaka, H. Taniguchi, K. Muro, Y. Komatsu ,E. Oki, K. Yamazaki, T. Misumi, T. Yoshino, T. Kato, and A. Tsuji
2023.10.19 - 2023.10.21
|
当院における骨転移ボードの取り組み-現状と課題-
三本芳、北岡智子、門田麻里 、佐々木牧子 、弘末美佐、 南場寛文 、喜安克仁、下川貴大、町田佐和、佐藤拓弥、栗岡勇輔、佐竹悠良、小倉拓也、植田太朗、藤原利輝、木村智樹
2023.10.19 - 2023.10.21
|
領域横断ワークショップ1 消化器がん 切除不能からのConversion therapy -領域を超えた概念と有効性の共有-
佐竹悠良
2023.10.18 - 2023.10.21
|
教育セッション20 胃癌治療UPDATE
佐竹悠良
2023.10.18 - 2023.10.21
|
irAE大腸炎に対するステロイド漸減中に下痢が再燃し、診断に難渋した食道癌多発大腸転移の1例
佐藤拓弥，栗岡勇輔，北川博之，佐竹悠良
2023.9.17 - 2023.9.17
|
複合免疫療法による有害事象鑑別の重要性を痛感した一例
小嶋 咲絵、 栗岡 勇輔、佐藤拓弥、佐竹 悠良
2023.7.23 - 2023.7.23
|
消化器癌化学療法 up to data
佐竹悠良
2023.7.9 - 2023.7.9
|
RAS status in circulating-tumor DNA after chemotherapy in RAS mutant mCRC:the RASMEX study (JACCRO CC-17)
Shinichi Nishina, Naoki Izawa, Megumu Watabe, Toshihiko Matsumoto, Masato Kataoka, Akinori Sugaya, Tomomi Kashiwada, Eiji Oki, Akitaka Makiyama, Yoshihisa Yaguchi, Takashi Ohta, Tatsuya Toyokawa, Yasuyuki Miura, Kazuma Kobayashi, Yosuke Kito, Osamu Muto, Yoshinori Kagawa, Hironaga Satake, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii, Yu Sunakawa
2023.6.28 - 2023.7.1
|
当院における地域への早期緩和ケア調整の課題と展望
栗岡勇輔、佐藤拓弥 、弘末美佐、佐竹悠良
2023.6.23 - 2023.6.24
|
IL-6およびKL-6が治療効果判定マーカーとして有用であった悪性腹膜中皮腫の1例
佐藤拓弥, 坂本秀男, 栗岡勇輔, 佐竹悠良
2023.6.17 - 2023.6.18
|
FP療法治療歴のある食道癌 術後再発に対してNivolumab+Ipilimumab療法が奏功した一例
坂本秀男，佐藤拓弥，栗岡勇輔，佐竹悠良
2023.6.17 - 2023.6.18
|
当院でのがん遺伝子パネル検査の実施状況と結果の検討
栗岡勇輔、佐竹悠良、佐藤拓弥、田代真理、弘末美佐、藤原キミ、杉本健樹
2023.6.17 - 2023.6.17
|
CGP検査によりMEN１遺伝子の病的バリアントを検出し遺伝カウンセリングに至った胸腺非定形カルチノイドの1例
佐藤拓弥，栗岡勇輔、小嶋咲絵、佐竹悠良
2023.6.17 - 2023.6.17
|
A prospective study of FOLFIRI plus aflibercept as second-line treatment after failure of
FOLFOXIRI plus bevacizumab in patients with unresectable/metastatic colorectal cancer (CRC): EFFORT study
Hironaga Satake, Koji Ando, Hisateru Yasui, Yuji Negoro, Tatsuya Kinjo, Koutarou Yuge, Kenji Baba, Hiroyuki Orita, Keiji Hirata, Mototsugu Shimokawa, Akitaka Makiyama, Hiroshi Saeki, Eiji Oki, Hideo Baba
2023.6.2 - 2023.6.5
|
A Multicenter Randomized Phase II Trial Comparing CAPOXIRI + Bevacizumab with FOLFOXIRI + Bevacizumab as First-line Treatment in Patients with Metastatic Colorectal Cancer: Primary Results of the QUATTRO-II Study
H. Bando, H. Satake, D. Kotani, T. Hamaguchi, M. Shiozawa, T. Ikumoto, Y. Okita, T. Masuishi, Y. Kagawa, H. Yasui, E. Oki, Y. Komatsu, H. Taniguchi, K. Muro, M. Kotaka, K. Yamazaki, T. Misumi, T. Yoshino, T. Kato, and A. Tsuji
2023.6.2 - 2023.6.5
|
Modified (m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment of patients with unresectable RASand BRAFwild-type metastatic colorectal cancer: Survival analysis of the phase II randomized DEEPER trial by JACCRO
Yu Sunakawa, Manabu Shiozawa, Takanori Watanabe, Hirofumi Ota, Hisateru Yasui, Taichi Yabuno, Mitsuyoshi Tei, Mitsugu Kochi, Dai Manaka, Hisatsugu Ohori, Tatsuro Yamaguchi, Tamotsu Sagawa, Masahito Kotaka, Yutaro Kubota, Takashi Sekikawa, Masato Nakamura, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii, and Akihito Tsuji
2023.1.19 - 2023.1.21 ASCO
|
A case of drug-induced large vessel vasculitis with hoarseness as the chief complaint caused by pegfilgrastim during chemotherapy
Takuya Sato1, Hironaga Satake1, Takeki Sugimoto2
2022.12.2 - 2022.12.4 ESMO
|
Randomized phase III study of bi-weekly trifluridine/tipiracil plus bevacizumab vs trifluridine/tipiracile alone
Yamazki K, Satake H, Takashima A, Mizusawa J, Kataoka T, Fukuda H, Ishizuka Y, Suwa Y, Numata K, Shibata N, Asayama M Yokota M,
2022.9.9 - 2022.9.13 ESMO
|
TRESBIEN (OGSG 2101): Encorafenib, binimetinib and cetuximab for early recurrent Stage II/III BRAF V600E-mutated CRC
Shogen Boku1, Hironaga Satake2, Takashi Ohta3, Seiichiro Mitani4, Kentaro Kawakami5, Toshihiko Matsumoto1, Eiki Yamazaki6, Hiroko Hasegawa7, Tatsuki Ikoma1, Mamoru Uemura8, Toshifumi Yamaguchi6, Yasunobu Ishizuka9, Yukinori Kurokawa8, Daisuke Sakai10, Hisato Kawakami4, Toshio Shimokawa11, Toshimasa Tsujinaka12, Takeshi Kato13, Taroh Satoh14, Yoshinori Kagawa15
2022.9.9 - 2022.9.13 ESMO
|
A phase II study of resection followed capecitabine plus oxaliplatin for liver metastasis of colorectal cancer (REX study): final analysis.
Hiroshi Tamagawa1, Naotoshi Sugimoto2, Takanori Watanabe3, Hironaga Satake4, Kozo Kataoka5, Keiko Kamei6, Michiya Kobayashi7, Koji Munakata8, Mutsumi Fukunaga9, Masahito Kotaka10, Taroh Satoh11, Akiyoshi Kanazawa12, Takayasu Kurata13, Naohiro Tomita
2022.6.28 - 2022.7.2 ESMO
|
Efficacy of 2nd-line ramucirumab (RAM) plus FOLFIRI for RAS wild-type metastatic colorectal cancer (mCRC) by prior regimen: Subgroup analysis of the JACCRO CC-16
Yoshihiro Okita1, Akihito Tsuji1, Takanori Watanabe2, Hironaga Satake3, Masahiro Goto4, Hisateru Yasui3, Masato Nakamura5, Tamotsu Sagawa6,
2022.6.28 - 2022.7.2 ESMO
|
Plasma RAS dynamics and efficacy of anti-EGFR rechallenge in patients with RAS/BRAF wild-type metastatic colorectal cancer: REMARRY and PURSUIT trials
Yoshinori Kagawa1, Daisuke Kotani2, Hideaki Bando2,3, Naoki Takahashi4, Yosuke Horita5, Akiyoshi Kanazawa6, Takeshi Kato7, Koji Ando8, Hironaga Satake9, Eiji Shinozaki10, Yu Sunakawa11, Atsuo Takashima12, Kentaro Yamazaki13, Satoshi Yuki14, Hiromichi Nakajima2, Yoshiaki Nakamura2,15, Masashi Wakabayashi16, Hiroya Taniguchi2,3,15, Takashi Ohta17, Takayuki Yoshino2
2022.6.28 - 2022.7.2 ESMO
|
A multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab and FOLFOXIRI plus bevacizumab as the first-line treatment for metastatic colorectal cancer: A safety analysis of the QUATTRO-II study
T. Masuishi 1, H. Bando 2, H. Satake 3, D. Kotani 2, T. Hamaguchi 4, M. Shiozawa 5, T. Ikumoto 6, Y. Kagawa 7, H. Yasui 8, T. Moriwaki 9, H. Kawakami 10, S. Boku 11, E. Oki 12, Y. Komatsu 13, H. Taniguchi 1, K. Muro 1, M. Kotaka 6, K. Yamazaki 14, T. Misumi 2, T. Yoshino 2,
2022.6.28 - 2022.7.2 ESMO
|
Plasma RAS dynamics and anti-EGFR rechallenge efficacy in patients with RAS/BRAF wild-type metastatic colorectal cancer: REMARRY and PURSUIT trials
Yoshinori Kagawa1, Daisuke Kotani2, Hideaki Bando2,3, Naoki Takahashi4, Tetsuya Hamagushi5, Akiyoshi Kanazawa6, Takeshi Kato7, Koji Ando8, Hironaga Satake9, Eiji Shinozaki10, Yu Sunakawa11, Atsuo Takashima12, Kentaro Yamazaki13, Satoshi Yuki14, Hiromichi Nakajima2, Yoshiaki Nakamura2,15, Masashi Wakabayashi16, Hiroya Taniguchi2,3,15, Takashi Ohta17, Takayuki Yoshino2
2022.6.3 - 2022.6.7 ASCO
|
Analysis of plasma angiogenesis factors on the efficacy of 1st-line (1L) chemotherapy (chemo) combined with biologics in RAS wild-type metastatic colorectal cancer (mCRC); Results from GI-SCREEN CRC Ukit study.
Satoshi Yuki1), Yu Sunakawa2), Kentaro Yamazaki3), Hiromichi Shirasu3), Hiroya Taniguchi4), Toshiki Masuishi4), Manabu Shiozawa5), Hideaki Bando6), Tomohiro Nishina7), Hisateru Yasui8), Takashi Ohta9), Naoki Takahashi10), Tadamichi Denda11), Taito Esaki12), Hisato Kawakami13), Hironaga Satake14), Atsuo Takashima15), Yukiko Abe16), Shogo Nomura6), Takayuki Yoshino6)
2022.6.3 - 2022.6.7 ASCO
|
A Single-arm, Open-label Phase 2 Study of Apalutamide (APA) plus goserelin (GOS) for patient (pts) with Locally Advanced or Recurrent/Metastatic (R/M) and Androgen Receptor (AR)-expressing Salivary Gland Carcinoma (SGC)
Yoshitaka Honma1, Nobuya Monden2, Keisuke Yamazaki3, Satoshi Kano4, Hironaga Satake5, 6, Shigenori Kadowaki7, Toshitaka Nagao8, Tomohiko Nakatogawa9, Koji Fujii9, Yosuke Koroki9, Junya Aoyama9, Shohei Ouchi9, Sharon McCarthy10, Sabine Brookman-May10, Suneel Mundle10, Jinhui Li10, Yuichiro Tada1
2022.6.3 - 2022.6.7 ASCO
|
|
すべて表示
５件表示
|
